The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.
Dr Mascarenhas on the Goals of the Phase 1/2 KRT-232-109 Study in Myelofibrosis
August 21st 2023John Mascarenhas, MD, discusses the goals of the phase 1/2 KRT-232-109 study evaluating the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients with primary or secondary myelofibrosis and highlights the eligibility criteria of this trial.
Dr Mascarenhas on the Rationale for the KRT-232-109 Study in Secondary Myelofibrosis
August 17th 2023John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.
Rusfertide Improves Efficacy Vs Placebo in Phlebotomy-Dependent Polycythemia Vera
Marina Kremyanskaya, MD, PhD, details the outcomes of the phase 2 trial, expands on the potential implications for rusfertide in the treatment of patients with PV, and detailed the next steps for investigating the agent in this patient population.
Up-front Testing Is Imperative for Treatment Decisions in RET+ NSCLC
July 29th 2023Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.
Rusfertide Offers Durable Hematocrit Control in Phlebotomy-Dependent Polycythemia Vera
June 11th 2023Rusfertide demonstrated freedom from phlebotomy, sustained hematocrit control, and 12-week treatment completion in 69.2% vs 18.5% of patients with phlebotomy-dependent polycythemia vera who received placebo, meeting the primary end point of the phase 2 REVIVE trial.
Dr Mascarenhas on the Background of the MANIFEST-2 Trial in Myelofibrosis
May 11th 2023John Mascarenhas, MD, discusses the background of the phase 3 MANIFEST-2 trial investigating the combination of pelabresib and ruxolitinib vs ruxolitinib plus placebo in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.
Dr Brunner on the Role of the Dermatologist in BPDCN Diagnosis and Treatment
April 11th 2023Patrick M. Brunner, MD, discusses how collaboration between dermatologists and oncologists is critical for both accurate diagnosis and the selection of effective treatment approaches for patients with blastic plasmacytoid dendritic cell neoplasm.
Imetelstat Displays Early Efficacy in Myelofibrosis; Phase 3 Trial Is Underway
The first-in-class telomerase inhibitor imetelstat is poised to expand the myelofibrosis treatment armamentarium should it prove safe and effective in the newly initiated phase 3 IMpactMF trial.